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licenses/by/4.0/).Abstract Objective: To determine the prevalence of sexual dysfunction and to identify the
factors associated with sexual dysfunction in young adult childhood cancer survivors.
Methods: All survivors of childhood cancer (aged 19e40 years) in Sweden were invited to this
population-based study, and 2546 men and women (59%) participated. Sexual function was
examined with the PROMIS Sexual Function and Satisfaction Measure. Logistic regression
was used to assess the differences between survivors and a general population sample
(n Z 819) and to identify the factors associated with sexual dysfunction in survivors.
Results: Sexual dysfunction in at least one domain was reported by 57% of female and 35% of
male survivors. Among females, dysfunction was most common for Sexual interest (36%),
Orgasm e ability (32%) and Vulvar discomfort e labial (19%). Among males, dysfunction
was most common for the domains satisfaction with sex life (20%), Sexual interest (14%)
and Erectile function (9%). Compared with the general population, male survivors more
frequently reported sexual dysfunction in 2 domains (OR Z 1.67, 95% CI: 1.03e2.71), with
an increased likelihood of dysfunction regarding Orgasm e ability (OR Z 1.82; 95% CI: 1.01
e3.28) and Erectile function (OR Z 2.30; 95% CI: 1.18e4.49). Female survivors reported(E. Hovén).
tributed equally as co-last authors.
shed by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
E. Hovén et al. / European Journal of Cancer 154 (2021) 147e156148more dysfunction regarding Orgasm e pleasure (9% versus 5%, OR Z 1.86; 95% CI: 1.11
e3.13). A more intensive cancer treatment, emotional distress and body image disturbance
were associated with sexual dysfunction in survivors.
Conclusions: The findings underscore the need for routine assessment of sexual health in
follow-up care of childhood cancer survivors and highlight that those treated with more inten-
sive cancer treatment and who experience concurrent psychological concerns may benefit from
targeted screening and interventions.
ª 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
With an increased 5-year survival rate approaching 80%,
the population of long-term childhood cancer survivors
is growing [1]. Only in Europe, there are about 500,000
people living with a childhood cancer experience [2].
This is a group known to be at risk of physical and
psychological late effects [3,4], and many survivors suf-
fer from chronic health conditions [4]. Despite being
acknowledged as an integral part of health and quality
of life [5,6], data on the effect of childhood cancer on
sexual health in young adult survivors are limited.
Sexual dysfunction in childhood cancer survivors can
be secondary to physical, psychological and social im-
plications related to the cancer experience [7,8].
Abdominal/pelvic or total body irradiation as well as
certain types of chemotherapy can result in delayed or
arrested puberty, premature menopause and testicular
dysfunction [3]. Previous studies suggest that both male
[9e12] and female [13,14] survivors experience more
sexual dysfunction than siblings and peers in similar
ages.
Sexual dysfunction has been reported for 20e52% of
female and 20e32% of male survivors of childhood
cancer [6,13,15]. Reported problems include low inter-
est, erectile dysfunction, vaginal dryness, vaginal pain/
discomfort and difficulties enjoying sex [6,13,15e17].
Risk factors for sexual dysfunction among survivors
include female sex, older age at study, health problems
and low income [8]. In addition, a negative body image
[16e20] and depressive symptoms [9,12,15] have been
linked to sexual problems. How treatment and illness-
related factors affect survivors’ sexual function is not
clear. Some studies suggest that survivors of certain
types of cancer are at higher risk for sexual dysfunction
[12e14], but other studies show no such associations
[15].
The evidence concerning sexual dysfunction among
childhood cancer survivors is hampered by methodo-
logical limitations regarding sampling and measures
[6,15,21]. Large-scale, methodologically rigorous studies
using representative samples and validated measures
are, thus, needed to gain better knowledge about the
extent of sexual problems in survivors and how these areassociated with sociodemographic, psychological and
clinical factors. Such knowledge can be used to develop
targeted screening and interventions for this population.
The aim of this study was, therefore, to determine the
prevalence of sexual dysfunction and to identify factors




The study is part of the Fex-Can Childhood project,
whose methods are described in a study protocol [22].
This nationwide, population-based study combines
registry and survey data for cancer survivors and in-
cludes a general population sample described in detail
elsewhere [23].
2.2. Participants
Survivors were identified through the National Quality
Registry for Childhood Cancer (NQRCC), which in-
cludes all individuals diagnosed with paediatric cancers
in Sweden. Eligible participants were diagnosed between
ages 0 and 17 and were 19e40 years of age and residents
in Sweden at the time of enrolment. Exclusion criteria
were as follows: unable to read/write in Swedish, self-
reported poor health and/or cognitive impairment that
prevented survey completion.
For the comparison group, a random sample (1000
women; 1000 men) from the general population aged
19e40 was identified by the Swedish population registry
and invited to the study [23]. The same exclusion criteria
as for survivors were used. Additionally, individuals
who reported treatment for cancer were excluded.
2.3. Procedure
The survey was sent to potential participants together
with a letter describing the study. Participants could
complete the survey via paper or Web, and non-
responders received two reminders. Data for survivors
were collected from August 2019 to February 2020 and
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Ethical approval was granted by the Regional Ethical
Review Board in Stockholm, Sweden (approval number:
2015/1609-31; 2018/2688-32; 2019/01066; 2019/04603).
2.4. Measures
Participants completed established self-report in-
struments together with study-specific items on use of
antidepressants, sexual orientation and sociodemo-
graphic factors.
Sexual function was measured by the Patient-
Reported Outcomes Measurement Information System
(PROMIS) Sexual Function and Satisfaction Measure
(SexFS) version 2.0 [24]. The following domains were
answered by females: Vaginal lubrication, Vaginal
discomfort, Vulvar discomfort e clitoral and Vulvar
discomfort e labial. The Erectile function domain was
answered by males. Four gender-neutral domains were
used: Satisfaction with sex life, Interest in sexual activ-
ity, Orgasm e ability and Orgasm e pleasure. All re-
spondents completed items related to Interest in sexual
activity, whereas remaining domains were completed
only by respondents who had been sexually active. In
the questionnaire, sexual activity was defined as sex with
a partner and/or solo sex including masturbation, oral
sex and intercourse. Domain scores were transformed to
a T-score metric, where 50 represents the mean for the
American general population (standard deviation [SD]
Z 10) [24]. As recommended by the PROMIS network
(http://www.nihpromis.org/), a cut-off of 1 SD from
mean was used to define sexual dysfunction. The SexFS
has shown adequate construct, content and known-
groups validity and test-retest reliability [24e26]. The
items were translated into Swedish and linguistically
validated in accordance with FACITrans and PROMIS
procedures [27].
Body image disturbance was assessed using the
Swedish version of the Body Image Scale (BIS). BIS
assesses body image discomfort in general (five items)
and in relation to cancer and its treatment (five items)
[28]. In line with previous research on non-cancer pop-
ulations [29], the comparison group responded only to
the five general items. The total sum score was used in
this study, with higher scores indicating more distur-
bance. BIS has shown clinical validity, high test-retest
reliability and satisfactory internal consistency [28,30].
Emotional distress was assessed using the Swedish
version of The Hospital Anxiety and Depression scale
(HADS) [31]. HADS has shown satisfactory internal
consistency and concurrent validity [32,33]. In this
study, the two subscales assessing symptoms of anxiety
and depression were combined in one overall score
(range 0e42), with higher scores indicating greater
emotional distress.
Clinical data were retrieved from the NQRCC
including cancer diagnosis, date of diagnosis, age atdiagnosis and treatment. Diagnoses were classified
according to the International Classification of
Childhood Cancer, 3rd revision [34]. Each child’s
treatment was categorised by a paediatric oncologist
using the Intensity of Treatment Rating scale (ITR-
3.0), a psychometrically validated measure of treat-
ment intensity of current treatment protocols in pae-
diatric oncology [35]. Different disease and/or
treatment modalities were classified according to one
of the four intensity levels, from level 1 (minimally
intensive) to level 4 (most intensive).2.5. Analyses
Clinical and sociodemographic characteristics of groups
were compared by gender using Student’s t-tests and
chi-square tests. Prevalence of sexual dysfunction was
compared between survivors and the comparison group
using logistic regression, adjusted for sociodemo-
graphics (age at study, education, relationship status,
having children and country of birth). To identify the
factors associated with dysfunction in survivors, logistic
regression models were conducted for each SexFS
domain and for dysfunction in two or more domains.
The following potential factors were selected a priori
based on the literature: age at diagnosis, time since
diagnosis, age at study, education, country of birth,
relationship status, sexual orientation, use of antide-
pressants, having children, type of cancer, treatment
intensity, body image disturbance and emotional
distress. First, each factor was examined in bivariate
analyses, using simple logistic regression and chi-square
tests as appropriate. Factors associated with dysfunc-
tion in the respective domain (P < 0.10) were thereafter
analysed using multivariable logistic regression.
All tests were two-tailed with P < 0.05 denoting
statistical significance. Analyses were performed using
SPSS Statistics version 25 (IBM Corp., Armonk, N.Y.,
USA).3. Results
3.1. Study participants
Of the 4328 survivors approached, 90 survivors were
excluded due to unknown address (n Z 49), living
outside Sweden (n Z 3), cognitive dysfunction (n Z 32)
and administrative failure (n Z 6). Study participants
were 2546 survivors (59% response rate), of which 1333
females (67% response) and 1213 males (52% response).
Table 1 shows the characteristics of the participants.
Among survivors with leukaemia (most common diag-
nosis), 65% of females and 56% of males had received
moderately intensive treatment, whereas 35% and 44%,
respectively, had undergone very/most intensive treat-
ment. More detailed information on intensity of
Table 1
Sociodemographic, psychological and clinical characteristics of the study sample.
Survivors The comparison group
Female (n Z 1333) Male (n Z 1213) Female (n Z 493) Male (n Z 326)
No. (%) No. (%) No. (%) No. (%)
Sociodemographics
Age at study, years
Mean (SD) 28.8 (6.1)* 29.2 (6.1) 29.7 (6.1) 29.3 (6.4)
Country of birth
Sweden 1272 (95.8)*** 1157 (95.9)*** 422 (85.6) 271 (83.4)
Other 56 (4.2) 50 (4.1) 71 (14.4) 54 (16.6)
Highest education
University 745 (56.1) 523 (43.3) 283 (57.8) 150 (46.3)
Upper secondary 479 (36.1) 589 (48.8) 179 (36.5) 153 (47.2)
Elementary 47 (3.5) 51 (4.2) 18 (3.7) 13 (4.0)
Other 56 (4.2) 45 (3.7) 10 (2.0) 8 (2.5)
In a relationship
Yes 940 (70.8)*** 728 (60.4)*** 394 (80.6) 231 (71.5)
Have children
Yes 495 (37.3)*** 368 (30.7)** 230 (46.8) 127 (39.2)
Sexual orientation
Heterosexual 1178 (89.2) 1137 (94.4) 454 (92.7) 307 (94.8)
Homosexual 20 (1.5) 20 (1.7) 6 (1.2) 7 (2.2)
Bisexual 83 (6.3) 23 (1.9) 26 (5.3) 7 (2.2)
Othera 27 (2.0) 11 (0.9) 3 (0.6) 3 (0.9)
Prefer not to answer 13 (1.0) 13 (1.1) 1 (0.2) e
Psychological outcomes
Emotional distress, HADS
Mean (SD) 12.6 (7.6) 9.96 (6.7) 11.99 (7.4) 9.51 (5.9)
Body image, BIS
Mean (SD) 8.6 (7.3)*** 5.8 (6.0) 5.2 (3.6) 3.2 (2.7)
Clinical characteristics
Age at diagnosis, years
Mean (SD) 7.4 (5.4) 7.8 (5.4)
0e5 years of age 615 (46.1) 496 (40.9)
6e12 years of age 383 (28.7) 404 (33.3)
13e17 years of age 335 (25.1) 313 (25.8)
Time from diagnosis, years
Mean (SD) 20.9 (7.8) 20.9 (7.8)
Range 1e38 1e37
Type of cancerb
Haematological cancers 603 (45.3) 615 (50.7)
Leukaemia (I) 418 (31.4) 377 (31.1)
Lymphoma (II) 185 (13.9) 238 (19.6)
CNS tumours (III) 310 (23.3) 267 (22.0)
Solid tumours 417 (31.4) 331 (27.3)
Neuroblastomas and other peripheral
nervous cell tumours (IV)
55 (4.1) 39 (3.2)
Retinoblastomas (V) 32 (2.4) 20 (1.6)
Renal tumours (VI) 84 (6.3) 62 (5.1)
Hepatic tumours (VII) 11 (0.8) 14 (1.2)
Malignant bone tumours (VIII) 58 (4.4) 57 (4.7)
Soft-tissue sarcomas (IX) 66 (5.0) 76 (6.3)
Germ-cell, trophoblastic, and other
gonadal tumours (X)
68 (5.1) 44 (3.6)
Carcinomas and other malignant
epithelial neoplasms (XI)
43 (3.2) 19 (1.6)
Other and unspecified malignant
neoplasms (XII)
3 (0.2) 0 (0.0)
Treatment modality
Chemotherapy 945 (70.9) 887 (73.1)
Surgery 504 (37.8) 412 (34.0)
Radiotherapy 282 (21.2) 262 (21.6)
Cranial irradiation 155 (11.6) 142 (11.7)
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Table 1 (continued )
Survivors The comparison group
Female (n Z 1333) Male (n Z 1213) Female (n Z 493) Male (n Z 326)
No. (%) No. (%) No. (%) No. (%)
Hematopoietic stem cell transplantation 83 (6.3) 99 (8.2)
Intensity of treatmentc
Least intensive 156 (11.7) 119 (9.8)
Moderately intensive 669 (50.2) 613 (50.6)
Very intensive 330 (24.8) 312 (25.8)
Most intensive 178 (13.4) 169 (13.9)
Relapse/second malignant neoplasm
Yes 148 (11.1) 124 (10.2)
CNS, central nervous system; BIS, Body Image Scale; HADS, Hospital Anxiety and Depression scale.
*, **, *** Difference in comparison with females/males in the comparison group at *P < 0.05 **P < 0.01 ***P < 0.001.
a Includes individuals who reported not knowing, being pansexual, queer or asexual.
b According to the International Classification of Childhood Cancer, third edition (ICCC-3) [34].
c According to the Intensity of Treatment Rating (ITR-3.0) [35].
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For survivors, female responders and non-responders
did not differ in demographic or clinical characteris-
tics. Among males, responders were older (mean Z 29
and 28 years, respectively; P < 0.05), and time since
diagnosis was longer than for non-responders
(mean Z 21 and 20 years, respectively: P < 0.05).
Sociodemographic characteristics were compared
between survivors and the comparison group (n Z 819,
42% response rate). Compared with survivors, more
females and males in the comparison group were born
outside Sweden, were partnered and had children (Table
1). Moreover, females in the comparison group were
older at the time of study.3.2. Prevalence of sexual dysfunction
More than half of female (57%) and one-third of male
(35%) survivors reported a dysfunction in at least one
domain during the last month, and about one-fifth
(22%) of females and one-tenth of males (13%) reported
dysfunction in at least two domains (Table 2). Among
females, sexual dysfunction was most common in the
domains of Interest in sexual activity, Orgasm e ability
and Vulvar discomfort e labial. The most commonly
reported sexual dysfunction in male survivors concerned
Satisfaction with sex life, Interest in sexual activity and
Erectile dysfunction. For prevalence of dysfunction by
ICCC-3 group diagnosis, see Suppl. Table 2.
Female survivors were more likely to report
dysfunction in Orgasm e pleasure than females in the
comparison group (OR Z 1.86, 95% CI: 1.11e3.13)
(Table 2). Male survivors were more likely than males in
the comparison group to report dysfunction in two or
more domains (OR Z 1.67, 95% CI: 1.03e2.71) (Table
2). Specifically, male survivors were more likely to
report dysfunction in Orgasm e ability (OR Z 1.82,95% CI: 1.01e3.38) and Erectile function (OR Z 2.30,
95% CI: 1.18e4.49).
3.3. Factors associated with sexual dysfunction in
survivors
Female survivors who were partnered and with a higher
education were less likely to report dysfunction in
certain domains (Table 3). Females with children and
who were born outside Sweden were more likely to
report dysfunction regarding Interest in sexual activity,
whereas females who reported a sexual orientation other
than heterosexual were less likely to report dysfunction
in this domain. Females who had received more inten-
sive treatment and with greater body image disturbance
were more likely to report dysfunction in two or more
domains. Furthermore, female survivors with greater
emotional distress were more likely to report dysfunc-
tion in all outcomes.
Males in a relationship were less likely to report
dysfunction in two or more domains, and males with a
more intensive treatment were more likely to report
dysfunction related to Orgasm e pleasure (Table 4).
Male survivors with a higher educational attainment
were less likely to report dysfunction in the domain
Interest in sexual activity. Moreover, male survivors
with greater emotional distress and greater body image
disturbance were more likely to report dysfunction in
two or more domains.
4. Discussion
This is one of the most comprehensive studies to date
on sexual dysfunction in young adult survivors of
childhood cancer. About half of the female and one-
third of the male survivors reported at least one current
sexual dysfunction. Among female survivors, dysfunc-
tion was most common in the domains Sexual interest,
Table 2
Prevalence of sexual dysfunctiona by sex in survivors and comparison
group; differences between groups were adjusted for sociodemo-
graphics (age at study, education, relationship status, having children




No. (%) No. (%)
Females n Z 1333 n Z 493
Satisfaction with
sex life
146 (13) 51 (12) 0.742 (0.74e1.52)
Interest in sexual
activity
474 (36) 156 (32) 0.115 (0.96-1-52)
Orgasm e ability 331 (32) 117 (28) 0.318 (0.88e1.48)
Orgasm e
pleasure
91 (9) 21 (5) 0.019 (1.11e3.13)
Vaginal
lubrication
94 (9) 30 (7) 0.114 (0.92e2.25)
Vaginal
discomfort








199 (19) 80 (19) 0.995 (0.74e1.35)
Dysfunction 1
domainb
750 (57) 263 (54) 0.263 (0.91e1.40)
Dysfunction 2
domainsb
239 (22) 77 (18) 0.057 (0.99e1.80)
Males n Z 1213 n Z 326
Satisfaction with
sex life
217 (20) 52 (17) 0.788 (0.66e1.37)
Interest in sexual
activity
163 (14) 32 (10) 0.095 (0.94e2.24)
Orgasm e ability 89 (8) 16 (5) 0.045 (1.01e3.28)
Orgasm e
pleasure
73 (7) 17 (56) 0.776 (0.61e1.93)
Erectile function 95 (9) 11 (4) 0.015 (1.18e4.49)
Dysfunction 1
domainb
418 (35) 98 (31) 0.528 (0.82e1.47)
Dysfunction 2
domainsb
145 (13) 24 (8) 0.038 (1.03e2.71)
CI, confidence interval; CNS, central nervous system.
Valid percentages.
Statistically significant (P < 0.05) differences in the logistic regression
multivariable models indicated in bold.
a Self-reported dysfunction defined as cut-off Z 1 SD above/below
the t-score mean of the norm population [24].
b Based on reports for the domains: Satisfaction with sex life, Interest
in sexual activity, Orgasm e ability, Orgasm e pleasure, Vaginal
lubrication (females only) and Erectile function (males only).
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survivors, sexual dysfunction was most frequently re-
ported in the domains Satisfaction with sex life, Interest
in sexual activity and Erectile function. While the
prevalence of sexual dysfunction among female survi-
vors was similar to that of women in the comparison
group, male survivors reported a higher prevalence of
dysfunction for two domains compared to men in the
general population sample. Corresponding to what hasbeen reported for the comparison group [23], increased
likelihood of sexual dysfunction in one or more domains
in survivors was associated with not having a partner,
low education, as well as concurrent emotional distress
and body image disturbance. Our results furthermore
show an increased likelihood of sexual dysfunction in
survivors subjected to a more intensive treatment.
In comparison with our general population sample,
both female and male survivors were significantly less
likely to have a partner and to have children. When
controlling for sociodemographic variables, we found
few differences in prevalence of sexual dysfunction be-
tween female survivors and women in the general pop-
ulation. This is in contrast to studies from the United
States (US), indicating that female survivors are at risk
for impaired sexual functioning across domains [13,14]
but corresponds with results of a Swedish study [11].
Future studies are needed to determine if the differing
results between our study and the US studies can be
explained by differences in sampling, measures, defini-
tions and/or cultural differences between the countries.
For example, the definition of sexual dysfunction in one
of the US studies [13] was based on the reports of the
controls, making the definition sensitive to selection bias
of the controls. The definition used in this study was,
instead, based on standard scores with thresholds to
identify clinically meaningful sexual dysfunction [25].
Moreover, the estimates of dysfunction in our compar-
ison group corresponds with previous results for general
population samples [29,36,37], highlighting that prob-
lems with sexual function are common, in particular
among women.
In contrast to our findings for females, male survi-
vors were at increased risk of sexual dysfunction
compared with men in the general population, with a
higher prevalence of dysfunction related to Orgasm e
ability and Erectile function. Thus, in line with a pre-
vious study [11], our results indicate that childhood
cancer can have adverse effects on certain domains of
sexual functioning, and that this is more evident in
male survivors. It is well known that men and women
differ in perceived sexual function and that sexual
dysfunction is more prevalent in women [23,36].
Therefore, analyses of survivors’ sex life should be
performed by gender and include appropriate non-
cancer comparison data, as in the present study.
Previous studies have shown conflicting results
regarding risk of erectile dysfunction in childhood
cancer survivors [9,10]. Erectile dysfunction can be
caused by a variety of reasons relating to psychologi-
cal, endocrine, vascular and neurological factors [38].
The increased risk of erectile dysfunction that we
observed might be related to both physical and psy-
chological impact of the cancer. Body image distur-
bance was associated with sexual dysfunction in several
domains for male as well as female survivors, high-
lighting this issue as a target for interventions aiming at
Table 3
Results of the multivariable logistic regression models for sexual dysfunction in female survivors. The model for each SexFs domain included only









Vaginal lubrication 2 domains above
cut-off
OR 95%CI OR 95%CI OR 95%CI OR 95%CI OR 95% CI OR 95%CI









0.38 0.25e0.58 0.54 0.41e0.72 0.67 0.41e1.08 0.77 0.55e1.09
Having children
















Use of antidepressants e no (ref)











1.08 1.05e1.11 1.05 1.03e1.07 1.03 1.01e1.05 1.08 1.04e1.12 1.05 1.02e1.09 1.08 1.06e1.11
Body image disturbance
(BIS)
1.03 1.00e1.06 1.01 0.99e1.03 1.02 1.00e1.05 1.01 0.97e1.04 1.05 1.01e1.08 1.03 1.00e1.05
BIS, Body Image Scale; CI, confidence interval; CNS, central nervous system; HADS, Hospital Anxiety and Depression Scale; OR, odds ratio; Ref,
reference category.
Statistically significant (P < 0.05) factors in the multivariable model indicated in bold.
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with adult survivors indicate that a negative body
image as a result of the cancer experience hinders
physical intimacy [39], which can explain our findings.
Furthermore, consistent with previous reports
[9,13,15], we found emotional distress to be linked to
sexual dysfunction. The associations between sexual
dysfunction and body image disturbance and
emotional distress, respectively, may be bidirectional
and underscore that sexual health interventions should
consider combining psychological (e.g. counselling)
and medical (e.g. hormones) treatment.
Conflicting results have been presented as to how
specific cancer treatments are associated with sexual
dysfunction [12e15]. Our findings demonstrate that the
very or most intensive cancer treatments put survivors,
particularly females, at increased risk for later sexualdysfunction. Patients treated with the very or most
intensive treatments according to ITR-3.0 include those
treated with hematopoietic stem cell transplantation
(HSCT) and with relapse protocols, those treated for
osteosarcoma, Ewing sarcoma and higher stages of
other solid tumours, as well as those treated for acute
myeloid leukaemia, acute lymphoblastic leukaemia with
high-risk/T-cell lymphoma protocols and brain tumours
with two or more modalities [35]. Risk of gonadotox-
icity is not specifically measured in the ITR-3.0 rating
system. However, cancer types in very or most intensive
treatments groups are treated with high cumulative
doses of alkylating chemotherapy, cranial or abdominal
irradiation or HSCT, which are associated with
increased risk of premature menopause, testicular
dysfunction and deficiency of sexual hormones. Inten-
sive treatment as a risk factor is an important
Table 4
Results of the logistic regression models for sexual dysfunction in male survivors. The model for each SexFs domain included only the factors that










Erectile function 2 domains above
cut-off
OR 95%CI OR 95%CI OR 95%CI OR 95%CI OR 95%CI OR 95%CI









0.17 0.11e0.26 0.43 0.28e0.65 0.77 0.49e1.20 0.54 0.30e0.95 0.43 0.25e0.72 0.30 0.19e0.46
Having children





















1.18 0.54e2.54 1.36 0.51e3.64 1.18 0.47e2.97
Emotional distress
(HADS)
1.07 1.04e1.10 1.04 1.01e1.07 1.01 0.98e1.05 1.08 1.04e1.12 1.03 0.99e1.07 1.05 1.01e1.08
Body image disturbance
(BIS)
1.06 1.03e1.09 1.03 1.00e1.06 1.07 1.03e1.11 1.05 1.01e1.10 1.08 1.04e1.13 1.08 1.04e1.11
BIS, Body Image Scale; CI, confidence interval; CNS, central nervous system; HADS, Hospital Anxiety and Depression Scale; OR, odds ratio; Ref,
reference category.
Statistically significant (P < 0.05) factors in the multivariable model indicated in bold.
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elucidate factors underpinning the higher risk observed
among these survivors.
The strengths of the present study include the large
population-based cohort, use of treatment information
from a national quality registry (NQRCC) with good
coverage, use of standardised measures and inclusion of
a randomly selected comparison group. Nevertheless,
some limitations should be recognised. Our estimates of
dysfunction rely on self-reports and were not validated
against, for example, structured interviews by pro-
fessionals experienced in diagnosing sexual disorders.
Furthermore, the definition of sexual dysfunction was
based on American norms; however, aspects of sexual
function and activity are similar between the countries
[36,40], including age for sexual debut. Moreover,
women and men in our comparison group report similar
rates of dysfunction as the US general population [36].
While our response rates are similar to Ref. [13] or
higher [14] than other survey studies on this topic, there
is still a risk of participation bias. Non-sexually activeindividuals might be less likely to participate in studies
on sexuality, leading to sexual problems being under-
reported. Among male survivors, non-responders were
older than responders, but we do not believe that the 1-
year difference resulted in an overestimation of
dysfunction in this group. Finally, as the comparison
group differed from survivors in some sociodemo-
graphic characteristics the analyses between these
groups were adjusted accordingly.
5. Conclusions
Overall, young adult survivors of childhood cancer
report sexual functioning in line with peers, but male
survivors have more problems related to erectile func-
tion and orgasm. Furthermore, survivors are partnered
and have children to a lesser extent, indicating diffi-
culties in building intimate relationships. This un-
derscores the need for routine assessment of sexual
health in follow-up care of survivors. Survivors sub-
jected to a more intensive cancer treatment and who
E. Hovén et al. / European Journal of Cancer 154 (2021) 147e156 155experience concurrent psychological concerns are high-
risk subgroups who may benefit from targeted screening
and interventions.
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